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Abstract
Objective—To evaluate contraceptive adherence to the copper intrauterine device (Cu-IUD) and
the injectable depot medroxyprogesterone acetate (DMPA) among women with HIV in Lilongwe,
Malawi.
Methods—We randomized 200 HIV-infected women on HAART to either the Cu-IUD or
DMPA and followed these women prospectively, evaluating adherence and factors associated with
nonadherence.
Results—There was no difference in contraceptive adherence: 68% of Cu-IUD and 65% of
DMPA users were adherent at 48 weeks. Receiving first-choice contraceptive was not associated
with adherence. Women commonly cited partner’s disapproval as an indication for
discontinuation. Women who experienced heavy menstruation and first-time contraceptive users
were more likely to be nonadherent. Among ongoing users at study conclusion, 95% were happy
with their method, and 98% would recommend their method to a friend.
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Conclusion—Contraceptive adherence between the Cu-IUD and DMPA was similar at 1 year.
With similar adherence and similar high rates of satisfaction among users of both methods at 1
year, the Cu-IUD offers a hormone-free alternative to DMPA.
Implications—Adherence to the Cu-IUD and DMPA is similar at 1 year among HIV-infected
women on HAART in a randomized controlled trial. Despite high method satisfaction, partner
disapproval and heavy bleeding contribute to reduced adherence. Receiving a method that differs
from participant’s first-choice method did not influence adherence.
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1. Introduction
Of the estimated 33 million people living with HIV/AIDS worldwide, 16 million are women
[1]. Unsafe sexual practices in sub-Saharan Africa have generated high rates of HIV,
sexually transmitted infections and unintended pregnancy. Specifically, preventing
unintended pregnancy reduces maternal and child mortality, rates of mother-to-child
transmission of HIV and poverty. Therefore, improving family planning services in these
countries remains a key public health goal.
Although there is a high prevalence of injectable contraceptive use in many resource-limited
settings, specifically depot medroxyprogesterone acetate (DMPA), continuation of these
methods can be poor with studies reporting 12-month continuation of DMPA ranging from
23% to 78% [2–6]. Adherence to a contraceptive requires continuation of the method at
appropriate intervals for efficacy. For DMPA, individuals must receive injections at 3-month
intervals. In contrast, the copper intrauterine device (Cu-IUD) offers hormone-free, effective
protection from pregnancy for up to 12 years. In Malawi, a large unmet need for family
planning services remains. While contraceptive knowledge is almost universal, the
contraceptive prevalence rate is 42% among married women using any form of modern birth
control with only 0.2% of Malawian women using the intrauterine device (IUD) [7,8].
Research exploring contraceptive method adherence in sub-Saharan Africa and among HIV-
infected women is lacking. Further, there are no studies on adherence among women
receiving antiretroviral therapy (ART). With the increase of women receiving ART in
Malawi with “Option B Plus” (initiation of lifelong ART among all HIV+ pregnant women)
[9,10], understanding contraceptive use in this increasing population is critical. Women on
ART have recurrent clinic visits for medication where contraceptives can be incorporated
and thus adherence may be improved. Alternatively, these women may have other medical
concerns or medication side effects that may influence contraceptive adherence. We sought
to determine contraceptive adherence over 1 year with a randomized controlled trial (RCT)
comparing the Cu-IUD and DMPA among HIV-infected women on ART in Malawi. Based
on prior studies in developed [6] and developing countries [11], we hypothesized that among
our HIV-positive cohort in Malawi, adherence for the Cu-IUD would be greater at 1 year
than adherence to DMPA. Furthermore, we sought to determine factors associated with
adherence, satisfaction, side effects and adverse events associated with these methods.
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HIV+ women seeking family planning services were enrolled by study staff into an RCT
comparing the copper T380A IUD (Cu-IUD) to DMPA at the Lighthouse Clinic in
Lilongwe, Malawi. Prior to study implementation, comprehensive family planning provision
was established [12]. In Malawi, contraceptives are offered free of charge through the
Ministry of Health.
Women attending their ART visits who were interested in family planning were referred to
the study and assessed for their interest and eligibility. Eligibility criteria included: 18–45
years of age; HIV-positive status on ART for 6 months or longer; medical eligibility to
receive the Cu-IUD and DMPA according to World Health Organization (WHO) criteria
[13], Malawi National Reproductive Health Service Delivery Guidelines and clinical
assessment; desire to delay pregnancy for 12 months or longer; and a plan to stay in the
region for study duration. Genital tract infections were diagnosed and treated per Malawi
sexually transmitted infections guidelines [14] using a syndromic management approach.
The study protocol was approved by the Malawi National Health Science Research Council
and institutional review boards at Emory University and the University of North Carolina at
Chapel Hill (ClinicalTrials.gov identifier NCT01191203).
Women were randomly assigned to receive the Cu-IUD or DMPA at enrollment. The
randomization occurred in blocks of four and six using an online randomizer (http://
www.randomizer.org/form.htm) with allocations placed in sequentially sealed envelopes
prior to study initiation. Method allocation was not masked. One incorrect allocation to
DMPA resulted in 99 women receiving the IUD and 101 women receiving DMPA.
At enrollment, participants completed a questionnaire, had a complete physical examination
and received the allocated method. Follow-up visits were at 4, 12, 24, 36 and 48 weeks. At
all follow-up visits, a questionnaire assessing side effects, a pregnancy test and physical
examination were administered. At initial, 24- and 48-week visits, hemoglobin level was
determined; at initial and 48-week visit, CD4 count was collected. At each visit, male and
female condoms were provided and use encouraged. A bar of soap was given at each visit.
No other financial incentives were offered.
Statistical analyses were performed using STATA version 11[15]. The primary outcome was
contraceptive adherence. With 200 participants, we had an 80% power of detecting a 20%
difference in adherence to the Cu-IUD compared to DMPA at 1 year with a two-sided 95%
confidence interval (CI), assuming 20% loss to follow-up. We defined adherence for the Cu-
IUD as the length of continuous time with the Cu-IUD in place. If a Cu-IUD expulsion was
replaced at a visit, the individual was considered adherent. If the device was not replaced
then nonadherence was noted at that time. If Cu-IUD removal was requested, nonadherence
was noted at the time of removal. For DMPA, adherence was defined as the length of
continuous time between initial injection and 15 weeks after final injection [16,17]. The
individual was nonadherent if DMPA was administered beyond 15 weeks from prior
injection, if the subject declined DMPA, became pregnant or had a hysterectomy.
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Nonadherence was considered a single event. Individuals lost to follow-up were censored at
the last visit with the Cu-IUD in place or 15 weeks after the last DMPA injection.
The Kaplan–Meier method was used to estimate the probability of adherence. Differences in
adherence between the DMPA and IUD groups were tested with log-rank tests. Cox
proportional hazards models were used to estimate hazard ratios and CIs for adherence. A
multivariate model was refined with backwards elimination removing variables that did not
change the estimate by more than 10%. Differences in the frequency of side effects were
assessed using chi-square or Fisher’s Exact Tests. Paired t tests assessed changes in
hemoglobin or CD4 count.
3. Results
A total of 281 women were screened between August 2010 and January 2011; 81 (28.8%)
were ineligible or refused enrollment: 12 (14.8%) did not meet medical eligibility, 21
(25.9%) were on ART for less than 6 months and 48 (59.3%) desired a specific
contraceptive method. There were no differences between mean age, gravidity and parity
between enrolled and unenrolled. Of 200 women enrolled, mean age was 32.3 (SD=5.6,
median=32, range=18–48), gravidity of 3.7 (SD=1.8, median=4.0, range=0–11) and parity
of 3.3 (SD=1.8, median=4, range=0–11) (Table 1). At enrollment, 10 women reported
current hormonal contraceptive use: nine DMPA users (two assigned to DMPA and seven
assigned to IUD) and one pill user (assigned DMPA).
Overall, 133 (66.5%) women were adherent at 48 weeks following contraceptive initiation,
and cumulative adherence was similar between DMPA and Cu-IUD groups (Fig. 1). Of 99
Cu-IUD users, 67 were adherent at 48 weeks, 29 women chose removal, 1 died and 2 were
lost to follow-up. There were nine Cu-IUD expulsions; three replacements and six declining
replacement. Of 101 women who received DMPA, 66 were adherent at 48 weeks, 21 chose
to discontinue, 9 were late for injections, 1 had a hysterectomy, 2 became pregnant, 1 died
and 2 were lost to follow-up (Fig. 2).
The most common reasons for discontinuing the allocated method were side effects (19
women=11 Cu-IUD, 8 DMPA), partner’s request (12 women=9 Cu-IUD, 3 DMPA), no
longer being sexually active (6 women=2 Cu-IUD, 4 DMPA) and desire to get pregnant (4
women=2 Cu-IUD, 2 DMPA). One IUD removal was performed in the operating room via
dilation and curettage.
After multivariate adjustment, method was still not significantly associated with adherence
(Table 2). However, heavy menstruation during the study increased the likelihood of
nonadherence (HR=2.6, 95% CI=1.06–6.36) while prior hormonal contraceptive experience
decreased the likelihood of nonadherence (HR=0.51, 95% CI=0.31–0.85). Notably, the
concordance of the allocated method with the participant’s first-choice method was not
associated with adherence. Furthermore, there was no interaction between method received
and first-choice method in a stratified analysis: among women receiving their first choice,
the hazard ratio for adherence was 1.00 (95% CI=0.5–1.97) for DMPA and 1.63 (95%
CI=0.72–3.33) for IUD.
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Among those adherent to the method at the last visit, satisfaction was not significantly
different by method: 95% stated that they were happy with their method, and 98% would
recommend it to a friend. For those who discontinued, 96% and 58% reported being happy
with their contraceptive, and 94% and 81% would recommend their method to a friend on
the visit prior to discontinuation and at their discontinuation visit, respectively.
Cu-IUD use was significantly associated with heavy menstrual flow and cramps. DMPA
was significantly associated with amenorrhea and reductions in libido (Table 3). The mean
CD4 count at baseline and 48 weeks was unchanged for both groups (p=.56): 430.1
cells/mm3 (SD=245.0) and 464.2 cells/mm3 (SD=242.4) for the IUD group and 550.1
cells/mm3 (SD=237.5) and 599.5 cells/mm3 (SD=241.2) for the DMPA group. Hemoglobin
at baseline and 48 weeks was unchanged for both groups (p=.33). There was no significant
difference in the number of women who changed their ART regimen over the course of the
study (p=.40).
4. Discussion
In this RCT, we demonstrated that the Cu-IUD offers an acceptable, hormone-free
alternative to DMPA for HIV-positive women, with similar rates of adherence, high
satisfaction and safety among users at 1 year. Our findings seem to challenge those from an
RCT in Zambia [18] among HIV-infected women where 51% of the Cu-IUD group and 87%
of the hormonal contraceptive group were continuing at 2 years. This reported that high
hormonal contraceptive continuation may overestimate the actual method adherence rate.
However, our findings differ from those among healthy US women in which Cu-IUD
continuation was greater than for DMPA at 1 year (84% vs. 57%) [6]. Differences in
adherence in the US may be due to contraceptive experience as we found familiarity with
contraception was important for increased method adherence. Furthermore, HIV-positive
women may have different health concerns than noninfected women impacting adherence.
Prior studies note lower adherence to the Cu-IUD related to patient misconceptions about
safety, provider discomfort, lack of social marketing and culture-specific concerns [19,20].
As DMPA has been the most common contraceptive used in Malawi while the IUD is just
now being reintroduced, misconceptions about the IUD are likely to have a greater impact in
this setting. Although we did not provide standardized counseling during enrollment or
follow-up, providers reviewed common side-effects, misconceptions and management
strategies with the goal of reducing method discontinuations. Future efforts need to address
patient knowledge, community misconceptions, and social–cultural beliefs regarding
contraception, specifically the IUD.
Reasons for nonadherence to either method in our study were similar to those reported
among healthy and HIV-positive women in developing countries [5,21,22], including
menstrual irregularities, desire for fertility or no current sexual activity [21,23–25]. Partners’
desire to discontinue contraception was also common. Our counseling did not routinely
include partners. Several women also discontinued due to side effects, some of which may
not have been related to their method as evidenced by one patient who attributed generalized
illness to her IUD. Overall, side effects were rare and similar to common reported side
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effects. Counseling women specifically about expected bleeding changes is important since
heavy bleeding was a predictor of nonadherence. Notably, there was no difference in
hemoglobin at 1 year despite increased bleeding reported among IUD users.
Adverse events were uncommon. Although one woman in each group died during the study
follow-up, these were unlikely related to the contraceptive method. Two women became
pregnant on DMPA; yet, based on the estimated gestational ages at follow-up, these
pregnancies were likely conceived before DMPA became effective. The relatively high IUD
expulsion rate may have been associated with provider inexperience; providers began
placing IUDs concordant with study initiation. Although one woman needed to go to the
operating room for IUD removal, it was the missing string and limited provider experience
that led to hospital referral. One woman in the DMPA group had a hysterectomy, although
we were unable to determine the reason.
Our study has several limitations. First, we do not measure adherence past 1 year. Cu-IUD
adherence may improve with time compared to DMPA, supported by our findings of fewer
IUD discontinuations after 36 weeks compared to DMPA. Second, there are baseline
differences between the intervention arms with those in the IUD group having higher
education and lower rates of unintended pregnancy. However, controlling for these factors
did not impact rates of adherence or our conclusions.
A strength is that our primary endpoint was contraceptive adherence, defined as consistent
and correct use of a method, rather than method continuation which may underestimate the
impact of inconsistent use on contraceptive effectiveness. Evaluating adherence provides a
better estimate of actual time of contraceptive exposure and protection from unintended
pregnancy. We used 15 weeks as a cut off for adherence based on the WHO family planning
provider handbook [17], the basic guidance for practice in Malawi. This may be an
underestimate of DMPA effectiveness as evidence suggests that efficacy can extend for 17
weeks after an injection [16].
Another strength is the RCT design that removes potential patient selection and provider
bias within a population where the IUD is not commonly used and where differential beliefs
and health concerns could impact outcomes. Randomization in contraceptive studies is a
topic of debate in the family planning community. It is posited that method choice may be a
strong predictor of adherence and patient satisfaction such that randomization leads to a
discontinuation bias. We did not find this to be the case as contraceptive choice was not
associated with adherence. Overall method satisfaction was high, even among women
discontinuing, highlighting that discontinuation is not always due to method disapproval. It
is posited that the sample willing to be randomized may not be representative of the
population; however, most eligible patients were enrolled and similar to unenrolled. Our
results provide a good representation of contraceptive adherence in similar settings where
family planning is integrated into HIV care.
Recently, renewed concerns surfaced over the potential for increased transmission of HIV
and disease progression with hormonal contraception use [26,27]. However, not all studies
support this link [28,29], and methodological limitations across so few studies limit possible
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implications of the data thus far [30]. The WHO concluded that there was insufficient
evidence to support a change in the current guidelines on the use of hormonal contraceptives
[31]; yet, they encouraged further investigation on the impact of hormonal contraception and
HIV risk, along with increased promotion of consistent use of condoms and other
nonhormonal contraceptives. Demonstrating the feasibility and acceptability of an RCT and
similar adherence to the copper IUD among HIV-infected women can assist future research
efforts.
Among women with HIV, many were willing to accept a Cu-IUD for birth control as well as
participate in an RCT for contraception. The Cu-IUD may have many benefits that support
its promotion in sub-Saharan Africa where HIV is endemic, and we found that adherence to
the Cu-IUD was similar to DMPA among HIV-infected women at 1 year. As multiple
factors impact method adherence, including partner’s desire to discontinue, altering fertility
intentions and side effects, educational efforts need to address patient, provider and
community misconceptions related to family planning.
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Unadjusted Kaplan–Meier survival curve of adherence over time by study arm (p=.919).
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Study screening, enrollment and followup over 48 weeks. Cumulative adherence probability.
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Table 1
Baseline characteristics by study arm
Variable DMPA (n=101) IUD (n=99) p Value
Count (%) Count (%)
Concordance between first-choice method and assigned method 57 (56.4) 43 (43.4) .066
Age at enrollment [mean (SD)] 32.21 (5.22) 32.44 (6.03) .767
Education
 Less than primary completed (reference) 55 (54.5) 39 (39.4) .048*
 Primary completed but less than secondary completed 31 (30.7) 47 (47.5)
 Some education beyond secondary 14 (13.9) 13 (13.1)
Last pregnancy unintentional 77 (76.2) 60 (60.6) .046*
Ever had an abortion 32 (31.7) 23 (23.2) .226
Number of past pregnancies
 0 or 1 (reference) 7 (6.9) 10 (10.1) .421
 2 or more 94 (93.1) 89 (89.9)
Partners in the past year
 0 3 (3.0) 6 (6.1) .555
 1 92 (91.1) 88 (88.9)
 2 or more 6 (5.9) 5 (5.1)
Relationship status
 Not currently living with partner (reference) 23 (22.8) 30 (30.3) .227
 Currently living with partner 78 (77.2) 69 (69.7)
Partner desires more children 9 (8.9) 5 (5.1) .362
Partner support for birth control
 Partner does not support (reference) 8 (7.9) 5 (5.1) .553
 Partner supports 77 (76.2) 74 (74.7)
 Partner opinion unknown 16 (15.8) 20 (20.2)
Partner HIV status
 HIV positive (reference) 56 (55.5) 51 (51.5) .853
 HIV negative 10 (9.9) 11 (11.1)
 Partner status unknown 35 (34.7) 37 (37.4)
Previously used hormonal birth control method a 71 (70.3) 68 (68.7) .805




Hormonal contraceptive methods previously used: 39 (19.5%) oral contraceptive pills, 5 (2.5%) contraceptive implants and 128 (64%) DMPA.
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Table 3
Side effects by treatment arm
Variable IUD DMPA p
n (%) n (%)
Heavy menstrual flow 18 (18.2) 8 (7.9) .031*
Spotting 22 (22.2) 32 (31.6) .133
Amenorrhea 55 (55.6) 70 (69.4) .045*
Cramps 19 (19.2) 6 (5.9) .005*
Headache 27 (27.3) 30 (29.8) .704
Dizziness 17 (17.2) 13 (12.8) .395
Nausea 15 (15.2) 18 (17.8) .611
Breast tenderness 5 (5.1) 9 (8.9) .287
Weight gain 57 (57.6) 58 (57.4) .982
Weight loss 49 (49.5) 37 (36.6) .067
Depression 12 (12.1) 9 (8.9) .461
Reduction in libido 31 (31.3) 52 (51.4) .004*
Pain during sex 10 (10.1) 12 (11.8) .688
Abdominal pain 27 (27.3) 17 (16.8) .075
Vaginal discharge 3 (3.0) 8 (7.9) .226
Backache 31 (31.3) 30 (29.8) .805
Hair loss 6 (6.1) 3 (3) .478
*
p<.05.
Contraception. Author manuscript; available in PMC 2014 July 23.
